Physician profile
Christopher Morache
NPI 1689621567
$6,177.97
in general payments reported to CMS, 2019-2025
22 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.32 · 2020: $266 · 2021: $285 · 2022: $611 · 2023: $1,117 · 2024: $2,187 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,955 · Education: $6.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,954.73 |
| Education | $6.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $760.75 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $688.46 | 2023-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $650.22 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $576.25 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $446.44 | 2021-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $405.23 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $359.66 | 2021-2024 | Austedo Xr, Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $341.84 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $330.78 | 2022-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $286.34 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $251.63 | 2019-2021 | |
| Corium, LLC | $201.19 | 2022-2024 | Azstarys |
| Indivior INC. | $198.73 | 2022-2025 | Sublocade, Perseris |
| Lundbeck LLC | $166.42 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $141.25 | 2023-2025 | Sunosi, Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $80.86 | 2020-2021 | |
| Allergan, INC. | $77.85 | 2020 | |
| Almatica Pharma LLC | $62.52 | 2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $58.19 | 2022-2024 | Trintellix |
| Azurity Pharmaceuticals, INC. | $35.19 | 2023 | Horizant |
| Idorsia Pharmaceuticals US INC | $30.25 | 2023 | Quviviq |
| Biogen, INC. | $27.92 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Morache listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.